HOME > COLUMN

    COLUMN

    ページ

    COMMENTARY

    Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
    By Reiji Anasako

    Drug makers’ sales forces have continued to shrink over the last few years. As the shift from primary fields to specialty arenas and the loss of patent protection for major products have transformed drug makers’ product mix, fewer sales reps…

    COLUMN

    What Is the Price of a Work-Life Balance?
    By Philip Carrigan

    If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…

    FY2021 Drug Maker Employment Survey

    Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players

    The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

    INTERVIEW

    From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
    By Yoshinori Sagehashi

    Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…